Low & Bonar appoints Dr Giulia Nobili to its Board as Non-Executive Director

– UK, London –  Low & Bonar PLC (LON: LWB), today announced the appointment of Dr Giulia Nobili as a non-executive director. She will join the Board with effect from 10 July 2019.

Daniel Dayan, Executive Chairman of Low & Bonar, said: “Giulia Nobili has been working successfully in a variety of senior management positions in international banking and industry for 31 years. She has extensive experience in international capital markets, financial products and strategic corporate transactions, as well as operational and general management experience in major international corporations and mid-size companies. I look forward to working closely with Giulia as a director of Low & Bonar.”

About Dr Giulia Nobili

Giulia was appointed to the Board of the Company at the request of Sterling Strategic Value Fund S.A., SICAV-RAIF. Sterling is currently the largest investor in the Company.

Giulia is a member of the investment committee of Sterling, managing existing portfolio assets and assessing new investment opportunities. Before joining Sterling, Giulia had been the Group Director for business development and integration management for Diageo plc and the Group Director for strategy and business development for Cable & Wireless plc. Most recently, she was a partner at Ares Life Sciences, a Private Equity Fund active in the healthcare sector, and previously she spent 12 years in investment banking in London.

Under the provisions of the UK Corporate Governance Code, Dr Giulia Nobili will not be considered to be an independent Non-Executive Director.

For more information: https://www.lowandbonar.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.